
Solid Form Screening and Crystallization Process Development of a Clinical Phase II API
Abhijeet S. Sinha, Michael Morgen, and Arianna Nejely
Lonza
PURPOSE
Late-stage unexpected appearance of new solid forms of an API is costly and detrimental to meeting tight development timelines. In this case, inconsistency of the solid form was noted during manufacture of registration batches of Form 1. Solid form screening coupled with crystallization process development identified the lead form.

Material from different registration batch campaigns
OBJECTIVES
METHODS

RESULTS
Change in form of drug clearly identified by PLM and PXRD


10-Day slurry of Form 1 in different solvents


Increasing dielectric constant
Conversion of Form 1 to Form 2 is solvent dependent

Hypothetical diagram of energy states following Ostwald’s law of stages

Dissolution curves for drug
Micronized Form 2 matches the performance of Form 1
Final crystallization process for Form 2 of drug

CONCLUSIONS
A robust crystallization process for the thermodynamically favored Form 2 was developed and successfully transferred to manufacturing plant

Thermodynamic relationship between different forms
CONTACT INFORMATION: [email protected]
DISCLAIMER
All trademarks belong to Lonza or its affiliates or to their respective third party owners. The information contained herein is believed to be correct and corresponds to the latest state of scientific and technical knowledge. However, no warranty is made, either expressed or implied, regarding its accuracy or the results to be obtained from the use of such information and no warranty is expressed or implied.
